Detalles de la búsqueda
1.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Oncologist
; 28(10): 845-855, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37318349
2.
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Future Oncol
; 15(13): 1481-1491, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30839234
3.
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Haematologica
; 103(8): 1298-1307, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773593
4.
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Am J Hematol
; 91(12): 1206-1214, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27531525
5.
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Drugs
; 81(2): 257-266, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331989
Resultados
1 -
5
de 5
1
Próxima >
>>